NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PHAT

Phathom Pharmaceuticals Inc

Jun 30 • 04:00PM ET

9.59

Dollar change -0.15
Percentage change -1.54	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BPMC AXSM BTAI ACAD VKTX MDGL PTGX RDUS XENE

| Held by: IWM VTI SURI VXF IWN IBB SCHA IWO IWC VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.24	Insider Own	45.79%	Shs Outstand	69.64M	Perf Week	1.27%
Market Cap	669.52M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	0.13%	Shs Float	37.85M	Perf Month	122.51%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.91	Inst Own	47.30%	Short Float	29.16%	Perf Quarter	45.30%
Income	-345.79M	P/S	8.18	EPS this Y	42.39%	Inst Trans	-17.12%	Short Ratio	3.95	Perf Half Y	27.87%
Sales	81.86M	P/B	-	EPS next Y	87.00%	ROA	-106.28%	Short Interest	11.04M	Perf YTD	18.10%
Book/sh	-4.86	P/C	3.15	EPS next 5Y	-	ROE	-	52W High	19.71 -51.34%	Perf Year	-6.16%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	-10.82% 12.50%	ROIC	-165.71%	52W Low	2.21 333.94%	Perf 3Y	17.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.23%	Volatility	6.29% 18.03%	Perf 5Y	-78.77%
Dividend TTM	-	EV/Sales	12.48	EPS Y/Y TTM	-18.80%	Oper. Margin	-349.84%	ATR (14)	0.94	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.54	Sales Y/Y TTM	3055.71%	Profit Margin	-422.42%	RSI (14)	65.49	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	3.58	EPS Q/Q	7.67%	SMA20	9.25%	Beta	0.45	Target Price	19.88
Payout	-	Debt/Eq	-	Sales Q/Q	1391.58%	SMA50	67.43%	Rel Volume	0.50	Prev Close	9.74
Employees	427	LT Debt/Eq	-	Earnings	May 01 BMO	SMA200	9.21%	Avg Volume	2.79M	Price	9.59
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.82% -1.71%	Trades		Volume	1,403,957	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight	$23
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Loading…
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
08:00AM	Loading…
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire) -5.00%
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
09:35AM	Loading…
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-22-24 03:30AM	SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com) -5.38%
11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 08:00AM	Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 08:00AM	Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, VOQUEZNA Can Kick Some Acid (GlobeNewswire)
Mar-08-24 03:05PM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:57AM	Q4 2023 Phathom Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 01:51PM	PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.58%
01:38PM	Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ... (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients (GlobeNewswire)
Jan-31-24 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-14-23 08:00AM	Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital (GlobeNewswire) +7.98%
Dec-06-23 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD (GlobeNewswire) -5.36%
Nov-28-23 08:00AM	Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn (GlobeNewswire)
Nov-09-23 09:34AM	Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates (GlobeNewswire)
Nov-01-23 05:00PM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults (GlobeNewswire) -16.96%
Oct-30-23 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults (GlobeNewswire)
Oct-25-23 08:01AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 08:01AM	Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD (GlobeNewswire)
Sep-05-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.27%
Aug-21-23 08:00AM	Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application (GlobeNewswire)
Aug-10-23 08:01AM	Phathom Pharmaceuticals Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-14-23 04:40PM	These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham and They Have Over 60% Upside Potential (TipRanks)
Jul-10-23 08:26AM	Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies (Zacks)
Jul-07-23 08:38AM	3 Top Breakout Stocks Worth a Buy for Attractive Returns (Zacks)
06:52AM	Pleasing Signs As A Number Of Insiders Buy Phathom Pharmaceuticals Stock (Simply Wall St.)
Jun-12-23 08:01AM	Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD (GlobeNewswire)
Jun-09-23 04:01PM	Phathom Pharmaceuticals Announces Closing of Underwriters Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire) +5.61%
Jun-01-23 09:55AM	Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect? (Zacks)
08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-23 09:07AM	Institutional owners may ignore Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) recent US$66m market cap decline as longer-term profits stay in the green (Simply Wall St.)
May-26-23 09:55AM	Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-25-23 09:55AM	Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross? (Zacks)
May-23-23 07:41PM	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.41%
04:01PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:00PM	Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA (GlobeNewswire)
May-10-23 08:00AM	Phathom Pharmaceuticals Reports First Quarter 2023 Results (GlobeNewswire)
May-09-23 08:00AM	Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023 (GlobeNewswire)

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Topper James N	Director	May 21 '25	Buy	3.86	3,780	14,609	59,403	May 23 04:06 PM
Topper James N	Director	May 14 '25	Buy	3.32	6,300	20,919	55,623	May 15 04:17 PM
Topper James N	Director	May 13 '25	Buy	3.16	1,120	3,543	49,323	May 15 04:17 PM
Topper James N	Director	May 09 '25	Buy	3.22	35,602	114,616	35,602	May 13 04:13 PM
Topper James N	Director	May 12 '25	Buy	3.04	12,601	38,301	48,203	May 13 04:13 PM
Parikh Asit	Director	May 06 '25	Buy	2.60	5,000	13,000	90,500	May 08 05:27 PM
Parikh Asit	Director	May 07 '25	Buy	2.40	5,000	11,984	95,500	May 08 05:27 PM
Henderson Molly	CFO and CBO	Apr 07 '25	Sale	4.55	3,678	16,740	89,868	Apr 08 05:01 PM
Parikh Asit	Director	Sep 10 '24	Option Exercise	11.72	7,500	87,900	93,000	Mar 21 04:46 PM
Parikh Asit	Director	Mar 13 '25	Buy	4.42	10,000	44,200	85,500	Mar 17 04:27 PM
Henderson Molly	CFO and CBO	Jan 21 '25	Sale	6.59	6,583	43,371	93,546	Jan 23 04:24 PM
Nabulsi Azmi	Chief Operating Officer	Jan 21 '25	Sale	6.59	7,886	51,957	233,390	Jan 23 04:21 PM
Curran Terrie	President and Chief Executive	Jan 21 '25	Sale	6.59	19,109	125,884	360,465	Jan 23 04:19 PM
Nabulsi Azmi	Chief Operating Officer	Dec 19 '24	Sale	8.00	1,118	8,944	239,303	Dec 20 04:21 PM
Henderson Molly	CFO and CBO	Dec 19 '24	Sale	8.00	1,291	10,328	98,156	Dec 20 04:20 PM
KARBE FRANK	Director	Dec 13 '24	Buy	7.93	12,500	99,084	57,000	Dec 16 08:05 AM
Parikh Asit	Director	Dec 13 '24	Buy	8.12	10,000	81,248	75,500	Dec 16 08:05 AM
Nabulsi Azmi	Chief Operating Officer	Jul 15 '24	Sale	11.72	10,901	127,760	240,421	Jul 17 02:52 PM
Henderson Molly	CFO and CBO	Jul 15 '24	Sale	11.72	4,325	50,689	99,447	Jul 17 02:51 PM
Curran Terrie	President and Chief Executive	Jul 15 '24	Sale	11.72	33,848	396,699	377,734	Jul 17 02:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAT

Phathom Pharmaceuticals Inc

Upgrade your FINVIZ experience